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Abstract: 
Propensity scores (PS) are an increasingly popular method to adjust for confounding in 
observational studies. PS methods have theoretical advantages over traditional covariate 
adjustment, but their relative performance in real-word scenarios is poorly characterized. We 
used datasets from four large-scale cardiovascular observational studies (PROMETHEUS, 
ADAPT-DES, THIN, and CHARM) to compare the performance of traditional covariate 
adjustment and four commonly used PS methods: matching, stratification, inverse probability 
weighting and use of propensity score as a covariate. We found that stratification performed 
poorly with few outcome events, and inverse probability weighting gave imprecise estimates 
of treatment effect and undue influence to a small number of observations when substantial 
confounding was present. Covariate adjustment and matching performed well in all of our 
examples, although matching tended to give less precise estimates in some cases.  PS 
methods are not necessarily superior to traditional covariate adjustment, and care should be 
taken to select the most suitable method.  
 
Keywords: Propensity score, covariate adjustment, observational studies, bias, comparison 
of methods 
Abbreviations: BMI=body mass index; HPR=high platelet reactivity; IPW=Inverse 
probability weighting; MACE=major adverse cardiovascular event; PS=propensity score; 
RCTs=Randomized clinical trials;   
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Introduction 
Evaluation of therapeutic interventions generally fall into two categories, observational 
studies and randomized controlled trials (RCTs). The choice of treatment in observational 
studies may be influenced by patient characteristics; e.g. higher risk patients may be more or 
less likely to receive the intervention. Some of these differences are collected in standard 
databases, while others are not (e.g. frailty). In contrast, when studying the effect of an 
intervention in RCTs confounding from both measured and unmeasured variables is avoided, 
and RCTs are thus generally considered the highest form of scientific investigation. 
Nonetheless, accurate treatment effect estimates from observational databases can provide 
complementary value to RCTs. This is particularly true when RCTs enrol highly selected 
patients (yielding results not generalizable to all real world scenarios), are small (because of 
their greater complexity and cost), or are not feasible to conduct [1]. 
 
The traditional method to adjust for baseline differences between treatment groups in 
observational databases is covariate adjustment, where all relevant patient characteristics are 
included in a regression model relating the outcome of interest to the alternative treatments. 
A commonly cited concern is that such models might be over-fitted when the number of 
covariates is large compared to the number of patients or outcome events – a rule of thumb is 
to have at least 10 events per covariate included in the model.[2] However, more recent 
opinions favor relaxing this rule of thumb[3].   
 
 
 
Propensity score (PS) methods are increasingly being used in observational studies of 
cardiovascular interventions as an alternative to traditional covariate adjustment; many such 
- 4 - 
 
examples can be found published in JACC.[4-7] A propensity score is defined as the 
probability of a patient being assigned to an intervention given a set of covariates[8]. As the 
PS summarizes all patient characteristics into a single covariate, they reduce (although do not 
eliminate[9]) the potential for overfitting.PS methods aim to achieve some of the 
characteristics of RCTs by compensating for the fact that different patients had different 
probabilities to be assigned to the exposures under investigation. Their aim is to thus 
attenuate problems of confounding of patient characteristics and assignment to an 
intervention typically found in observational studies.  
 
Popular PS methods include stratification, matching, inverse probability weighting (IPW), 
and using the PS as a covariate in a conventional regression model.[10-12]] However there is 
lack of clear guidance on how to make a sensible choice between these various PS methods 
or traditional covariate adjustment for any given database. We therefore applied several 
propensity score methods to 4 large-scale observational cardiovascular datasets, to critically 
examine the specific advantages and pitfalls of the different methods, and to compare their 
results with classical covariate adjustment. 
 
 
Methods 
Datasets 
We analyzed data from the CHARM program[13], the ADAPT-DES study[14], the THIN 
study[15], and the PROMETHEUS study[16]. For each dataset, we focused on one “treatment” 
comparison and one outcome of prime interest. The overall goal was to produce relevant PS 
models across a range of different settings, so for some cases these choices differed from the 
primary objectives of the original publications. The terms “treatment” and “control” are used 
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throughout to simplify the language even though one study[14] performed comparisons for 
platelet reactivity. All outcomes studied were time-to-event with censoring occurring at the 
end of planned follow-up or at the time of patient withdrawal or lost to follow-up.  
 
The CHARM program[13]randomised 7,599 patients with chronic heart failure to candesartan 
versus placebo, with a median follow-up of 3.1 years. We herein investigate the association 
of treatment with beta-blockers at baseline (3,396 untreated, 4,203 treated) and all-cause 
death (1,831 events). That is, we utilize the CHARM program as an observational database 
for inference about the association of beta-blocker use and mortality risk. Our propensity 
score model contains cardiovascular risk factors, (age, sex, BMI, smoking, diabetes) as well 
as prior cardiovascular events and hospitalisations (18 variables in all). 
 
The ADAPT-DES study[14] investigated the relationship between high platelet reactivity 
(HPR) on clopidogrel (HPR 4,930 patients, not HPR 3,650 patients) to stent thrombosis and 
other cardiovascular events at 12 months follow-up in a prospective, multicentre registry of 
patients receiving drug-eluting stents. Herein we focus on stent thrombosis (56 events). The 
study authors reported an adjusted hazard ratio (HR) of 2.49 for HPR vs norther. Our 
propensity score model will contain information about age, sex, medication, diabetes, 
ethnicity, smoking, renal function and other cardiovascular risk factors (39 variables in all). 
 
The THIN population-based cohort study[15]compared 30,811 statin users with 60,921 
patients not using statins treated by the same general practitioners (total 91,732 patients) for 
several outcome events including all-cause mortality (17,296 events, HR 0.79). The inclusion 
criteria required at least 12 months of follow-up, thus the first year must be excluded due to 
the so-called immortality bias. Herein we investigate the effect of statin use on all-cause 
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mortality. The study authors reported an adjusted hazard comparing statin-users to non-users 
of 0.78. Previous a large RCT[17] in a similar patient population found a HR of 0.87. Our 
propensity score model will contain cardiovascular risk factors, age, sex, BMI, smoking, 
drinking, other medications and other diseases (48 variables in all). 
 
The PROMETHEUS cohort study[16]compared prasugrel (“treatment”) with clopidogrel 
(“control”) for MACE outcomes (death, myocardial infarction, stroke, or unplanned 
revascularization) at 90 days (1,580 events) in 19,914 patients (4,017 prasugrel, 15,587 
clopidogrel) using databases from 8 US hospitals. The authors reported an unadjusted HR of 
0.58 and an adjusted HR using a propensity score model of 0.89. Our propensity score model 
will contain cardiovascular risk factors, age, sex, BMI, smoking, prior cardiovascular events, 
as well as details about the implanted stent and an indicator for study centre (35 variables in 
all). 
 
Propensity scores – a brief overview 
The PS for an individual is defined as the probability of being assigned to “treatment” given 
all relevant covariates[8]. The PS is typically estimated using a logistic regression model that 
incorporates all variables that may be related to the outcome and/or the treatment decision. 
All such variables should be included in the logistic model irrespective of their statistical 
significance or collinearity with other variables in the model. However, variables that are 
exclusively associated with the treatment decision, but not the outcome, should not be 
incorporated[18]. As in any predictive regression model, any variable collected after the 
treatment decision should not be used. As far as possible, covariates identified as relevant in 
the four original studies will be incorporated in the PS models used here. Note that all 
relevant variables remain in the model regardless of their statistical significance. 
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For each covariate, individuals with the same PS should have, on average, the same 
distribution of that covariate irrespective of treatment decision (“covariate balance”). This 
can be checked using plots of the covariate balance or several diagnostic tests. 
 
After the PS has been calculated, there are several options for how to use them to estimate 
“treatment” effects. Note throughout that while PS methods strive to estimate the true 
“treatment effect”, the usual caveats for observational studies apply, such as the inability to 
include all relevant confounders (especially those unmeasured). As described below, popular 
PS methods include matching or stratifying observations based on the PS, inverse probability 
weighting (IPW) applied to each observation, or simply including the PS as an additional 
variable in a regression model. The more traditional covariate adjustment offers an alternative 
to PS techniques by simply incorporating all relevant covariates into the final model[19]. 
 
Four propensity score methods 
For each dataset the goal was to estimate the “treatment” effect on a time-to-event outcome 
using Cox proportional hazards models. After creating the PS for each individual, there are 
several ways to adjust for confounding.  
 
PS stratification splits the dataset into several strata based on the individual’s PS alone, 
without reference to their treatment (exposure) group. A treatment effect is then estimated 
within each stratum, and an overall estimated treatment effect is calculated by taking a 
(weighted) average across strata. Here, 5 and 10 strata with an equal number of individuals in 
each stratum are used. An alternative is to split the range of possible PS into equal parts, 
which usually results in fewer individuals in the more extreme strata. Stratification has the 
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additional advantage that effect estimates are available for each stratum, which may reveal 
potential heterogeneity of “treatment” effects across strata. 
 
PS matching tries to find one (or more) individuals with similar PS in the “treatment” and 
“control groups”. There are various methods to match individuals, but here we use 1:1 
nearest-neighbour matching with an added constraint that the difference between the PS 
(“caliper width”) may be at most 0.1 to avoid pairing dissimilar individuals. We chose this 
method for its computational simplicity. Following matching, the treatment effect is 
calculated by applying either a conventional (unmatched) regression model or a matched pair 
analysis to the set of patients who are successfully matched.[20] We opt for an unpaired 
analysis here due to its greater simplicity, noting that in our examples a paired analyses gave 
almost identical results (Supplementary Table 1).  
 
The matching process results in an analysis based upon only those patients who are 
successfully matched. Therefore, if the treatment effect varies according to patients’ 
characteristics and their likelihood of receiving treatment, the treatment effect estimated from 
this subset of patients may differ from the effect in the original study population. This issue is 
covered in greater detail in the discussion.  
 
Inverse probability weighting (IPW) uses the whole dataset, but reweights individuals to 
increase the weights of those who received unexpected exposures. This procedure can be 
thought of as producing additional observations for those parts of the target population from 
which there were few observations. It effectively generates a pseudo-population with near 
perfect covariate balance between treatment groups.[12] IPW applies weights corresponding to 
1/PS for patients in the “treated” cohort and 1/(1-PS) for those in the “control”cohort.PS 
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close to 0 (for the “treated”) or 1 (for the “control”) may be problematic for IPW due to the 
large weight assigned to these observations. We discuss below methods to resolve this issue 
such as trimming or truncating large weights.  
 
While these three PS methods aim to balance all covariates between the treatment and control 
groups, the more traditional covariate adjustment aims to control for covariate effects 
(confounding) using a prediction model for the outcome event (in our case a proportional 
hazards model for a time-to-event outcome). Care must be taken to specify the correct 
functional form for any covariates that may have non-linear effects. Covariate adjustment has 
its critics, but there is little practical evidence that it gives misleading results. For 
comparison, we provide the crude effect estimate as well as the covariate-adjusted effect 
estimate using all covariates from the PS models. 
 
Including the propensity score as an additional covariate in the regression model 
represents the fourth PS method examined. Alternatively, one could have only the PS and 
treatment in a model of the outcome of interest.  
 
Variations on propensity score methods 
There are several variations on the four PS methods presented above. A lack of covariate 
balance can be compensated for by using a “doubly robust” approach. The dataset can be pre-
processed by “trimming” away (removing) individuals with extreme PS. Alternatively, large 
IPW weights can be avoided by truncating the weights. 
 
“Doubly robust” methods incorporate relevant covariates both in the propensity score model 
and the outcome regression model for the treatment effect: this can compensate for 
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insufficient covariate balance.[21]  As the name implies, this approach offers some robustness 
to model misspecification either in the PS or the outcome regression model. It is 
recommended[8, 22] when using the propensity score as a covariate to also include individual 
covariates in the outcome regression model. When the method is used in this way, as we do 
throughout this report, it is “doubly robust”.  “Doubly robust” methods are also commonly 
used with IPW, but less frequently with matching or stratification, possibly due to the 
reduced sample size when using these methods. However, the doubly robust approach 
removes a key advantage of PS methods: having only one covariate in the final model. 
 
Trimming can be performed after the calculation of the PS. This involves dropping the 
individuals with most extreme PS values in both the “treatment” and “control” groups as they 
may lack a match in the other group and can be predisposed to residual confounding. This 
can help avoid extreme weights in inverse probability weighting, improve comparability 
between the exposures, and remove unusual “outlying” patients for whom the expected 
treatment (or control) was not chosen. Typical trimming methods might remove the most 
extreme 1% or 5% of all observations.  
 
Weight truncation reduces any “large” weight down to a maximum weight. There is no 
standard definition of a “large” weight for IPW. Here, we considered any weight above 10 to 
be “large” and reduced any weight greater than 10 down to this threshold. Removal of large 
weights is sometimes recommended for sensitivity analyses. However, complete removal of 
all individuals with weights larger than 10 may increase the imbalance between “treatment” 
and “control” groups.  
 
Standard errors and p-values 
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[23]All standard errors (SE) reported here are given on the effect (i.e. log HR) scale and we 
used the usual sandwich variance estimator when using IPW.[23] The calculation of p-values 
can then be done in the usual fashion. A special case is stratification, where it is necessary to 
aggregate SEs and p-values from multiple models. This is done by calculating the overall 
variance for a particular parameter as the weighted average of the variances for that 
parameter from each stratum and dividing by the number of strata[24]. Assuming asymptotic 
normality on the overall effect, p-values can then be calculated. 
 
Results 
PSs for the CHARM, ADAPT-DES, THIN, and PROMETHEUS studies showed a range of 
different distributions (Fig. 1). Full PS models are given in Supplemental Tables 2-5 and for 
comparison, covariate-adjusted models are given in Supplemental Tables 6-9.  Both CHARM 
and ADAPT-DES exhibited good overlap between the PS for the “treatment” and “control” 
groups. A single individual in the “control” group for ADAPT-DES had a PS close to zero 
and could be considered an outlier.  
 
In contrast, the THIN and PROMETHEUS studies showed markedly different PS 
distributions for the treatment and control groups. This indicates that it may be difficult to 
provide valid comparisons between the two groups. THIN had a substantial number of PS 
close to zero or one. There were 1,134 “treated” patients (4% of all “treated”) and 15,514 
“control” patients (25% of all “control”) with a PS less than 0.1. Conversely, there were 
2,235 “treated” individuals (7% of all “treated”) and 173 “control” patients (0.3% of all 
“control”) above a PS of 0.9. Clearly, there are key variables in the PS that played an 
important role in who did (and did not) receive a statin. Patients where PS and chosen 
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exposure strongly disagreed (high PS but received “control”, low PS but received 
“treatment”) may be atypical, but received large IPW weights. 
 
PROMETHEUS had a very large number of PS close to zero, especially in the “control” 
group receiving clopidogrel (7282 “control” individuals below PS 0.1, 47% of the “control” 
group). This indicates that key variables in the PS had a marked influence on physician 
choice of clopidogrel rather than prasugrel.  There were also a considerable number of 
patients in the “treatment” group receiving prasugrel, with a PS close to zero (330 “treated” 
individuals below PS 0.1, 8% of the “treated” group). These individuals may be unusual and 
may not offer a representative comparison with the other group. 
 
CHARM 
Results for CHARM, a non-randomised comparison of the effect of beta-blocker use versus 
control on all-cause death, showed excellent agreement across all PS methods and covariate 
adjustment (Fig. 2a). As expected, the crude estimate (first row) was different from the 
covariate adjusted estimate (second row) or estimates provided by the different PS methods 
(other rows). The adjusted HRs were all ~0.73, with 95% CIs ~0.65 to 0.81. SEs were very 
similar across all methods, and p-values were highly significant for all methods. 
 
ADAPT-DES 
The ADAPT-DES study, which investigated the relationship between HPR and the risk of 
stent thrombosis, produced similar HRs for most methods (Fig 2b). Covariate adjustment, 
matching, IPW and using the PS as a covariate all arrived at a HR of ~2.2 comparing HPR to 
not HPR. A notable exception is stratification, which showed an unstable result when using 
10 strata and a wider CI with 5 strata. Otherwise, SEs and p-values were comparable for all 
methods, although matching had slightly poorer precision. 
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An investigation of the strata for ADAPT-DES reveals that the relatively low number of 56 
events in the dataset was divided unevenly in the 10 strata (Supplemental Table 10). Two 
strata received only a single event, making precise estimation of the treatment effect within 
those strata impossible. These findings strongly suggest that stratification with this many 
strata should not be used when the number of events is sparse.  
 
THIN 
The different PS methods and covariate adjustment mostly produced similar results for the 
THIN study, arriving at HRs ~0.85 and a highly significant mortality reduction for those 
taking a statin (Fig. 2c). The exception was IPW, which estimated a smaller treatment effect 
with a wider CI. Trimming individuals with extreme PS from IPW gave similar results while 
truncating large weights in IPW brought the HR in line with the other methods. Similarly, a 
“doubly robust” approach of including all covariates in the final regression model also 
brought the HR in agreement with the other approaches. Additionally, a strong influence of 
confounders in this database was noted: the crude HR of 0.55 greatly exaggerated the 
treatment effect, due to the fact that individuals on statins tended to be at lower mortality risk. 
Note that from RCTs, a HR of approximately 0.87 is expected. 
A plot of the IPW weights revealed very large weights for some individuals (Fig. 3a), which 
may be why IPW produced different results from other methods. For 1,307 patients, weights 
exceeded 10. These 1.4% of patients had the same total weight as the 22% of patients with 
the lowest weights. This may have given undue influence to very few observations, which is 
especially problematic considering that those large weights were given to the most unusual 
individuals. The majority of the large weights were given to patients on statin treatment who 
the PS model strongly predicted would be controls (i.e. not taking a statin).  
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PROMETHEUS 
Results for the PROMETHEUS study (Fig. 2d), comparing prasugrel versus clopidogrel for 
risk of MACE events, showed substantial disagreement between the methods, although the 
results were non-significant for almost all methods. Covariate adjustment, stratification, IPW, 
and using the PS as a covariate all produced HRs of ~0.94. Matching showed a lower HR of 
~0.85. IPW without any modification had a much higher SE than other methods. 
Investigating the IPW weight distribution revealed very large weights for 8% (330 
individuals) of the “treatment” group (Fig. 3b), which may explain the stark change in HR 
seen when truncating large weights. The crude estimate of treatment (HR 0.59) is attributable 
to the marked confounding present; i.e. patients chosen to receive prasugrel tended to be at 
lower risk of MACE events. 
 
Further examination showed that covariate balance is insufficient for some methods. Figure 4 
compares the covariate balance for matching, stratification, and IPW using the absolute 
standardised difference between the “treatment” and “control” groups. Without use of PS 
methods, covariate balance was insufficient for almost all variables. Matching produced 
excellent balance for all variables. Stratification mostly achieved satisfactory covariate 
balance except for previous PCI, with age, hypertension, and prior CHF as borderline cases. 
IPW showed very poor covariate balance for previous PCI and poor or borderline balance for 
hypertension, previous MI, and prior PAD. Due to the lack of covariate balance, the results 
for stratification and IPW may be considered unreliable. 
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Effect of trimming and truncation of IPW weights  
We used PS trimming in the THIN and PROMETHEUS studies to attempt to reduce the 
impact of large weights in IPW. However, for both studies even 5% trimming was not 
sufficient to fully remove all large IPW weights from the datasets. Consequently, the standard 
errors for the estimated treatment effect remained large relative to other methods after 
trimming, particularly in PROMETHEUS (Fig 3d). We additionally applied 1% and 5% 
trimming and compared findings for each PS method and covariate adjustment on the 
trimmed datasets. However, trimming did little to reconcile differences in the estimates 
produced (Supplemental Figures S1-S4). Finally, we truncated large weights in the THIN and 
PROMETHEUS studies to a maximum of 10. In both examples, this resulted in a large 
reduction in the standard error and an estimated HR much closer to the crude estimate (Figs. 
3c-d). However, this brought the estimates closer to the other methods in THIN (Fig. 3c) 
whereas it took estimates further from other methods in PROMETHEUS (Fig. 3d). 
 
Discussion 
For observational cohort studies that compare alternative treatments (and other exposures), it 
has become standard practice to use propensity score (PS) methods to correct for selection 
biases and potential confounding when examining the relative risks (hazards) of event 
outcomes. While the principles of PS methods are clear, there exists a diversity of alternative 
approaches (e.g. propensity matching, stratification, inverse probability weighting (IPW) with 
or without trimming) alongside the more traditional method of covariate adjustment. 
Although there is a substantial methodologic literature on PS approaches with some limited 
guidance on which specific methods may be preferable[10, 11], there is no general agreement as 
to the choice of PS method that is best suited to any particular scenario. Thus, researchers 
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may choose a suboptimal method that preserves more bias and/or imprecision than is 
necessity. 
 
To provide insight to this common problem, we have here undertaken an in-depth assessment 
of many of the available PS and covariate-adjustment approaches as applied to four large-
scale cardiovascular studies. The present analysis illustrates the challenges faced in 
determining which methods actually produce the most valid results in different settings. 
 
Our first example, the CHARM study examining the impact of beta-blocker use at baseline 
on mortality in heart failure patients, is the most straightforward. The PS distributions for the 
17 chosen baseline variables showed considerable overlap between the two groups with no 
extreme values. In addition the study was large, with the two groups being of similar size. 
The results showed a consistency across all PS methods and also covariate adjustment. Note 
the crude estimate produced an exaggerated treatment effect, indicating the importance of 
taking confounding into account by using any of these methods. However, the extent of 
confounding is less extreme than in several of the other studies.  
 
The next example, ADAPT-DES comparing the risk of stent thrombosis in ACS patients with 
and without HPR, has some methodologic similarities to CHARM, but also the complication 
of having fewer outcome events (only 56 stent thromboses). Here, PS stratification performed 
badly, with too few events per stratum. PS matching and IPW showed good agreement, 
although the former had less precise estimates due to not using all patients in the matched 
analysis. Surprisingly, covariate adjustment with 39 covariates and only 56 events held up 
well, producing very similar estimates to IPW. 
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The last two examples, the THIN study comparing the mortality of individuals on and off 
statins, and the PROMETHEUS study comparing prasugrel versus clopidogrel for the risk of 
MACE events in ACS patients, both presented more of a challenge in choosing a robust PS 
method. The reason in both cases was the marked separation of PS probability distributions 
between the two groups: statin versus no statin and prasugrel versus clopidogrel respectively. 
In particular, there were a substantial number of PSs close to 0 and 1 in THIN and close to 0 
in PROMETHEUS. As a consequence, IPW included more than a few very influential 
individuals with very large weights in the IPW analysis. This in turn led to imprecise 
estimates of treatment effect and a worrying lack of covariate balance for some potentially 
important confounders. Additionally, in both these examples IPW analyses estimated HRs 
closer to the null. 
 
In both examples, the use of IPW in a “doubly robust” fashion (i.e. also including all 
covariates in the final analysis) induced compatibility with other methods, but did not reduce 
the SE thereby leaving the 95% CIs unduly wide. The use of trimming (e.g. removing the 5% 
of individuals with the most extreme PS) was somewhat helpful, but the imprecision of 
estimates remained greater than for other methods. The use of PS stratification also has its 
problems when there is marked selection bias, as seen in THIN and PROMETHEUS. This is 
because using only 5 (or 10) strata does not wholly correct for covariate imbalance. 
 
What can we learn from these experiences in order to make recommendations for the future 
use of PS methods and covariate adjustment? As in all studies, the primary analysis strategy 
should be pre-specified in advance. Post hoc selection of a preferred method after data 
exploration introduces bias and should only be considered for exploratory or sensitivity 
analysis.  
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One useful approach is to examine the baseline covariates prior to accessing any outcome 
data in order to determine which propensity score method (or covariate adjustment) may be 
most suitable given the characteristics of the PS, such as the degree of overlap in PS between 
treatment and control groups.  Even so, relying on one method of analysis (which may have 
its flaws) may be too restrictive and it is wise to pre-define a number of secondary sensitivity 
analyses using alternative approaches. This enables one to determine if there is a consistency 
of the findings regarding the estimated treatment “effect”, which if present instills confidence 
in the primary results. 
 
But for any specific study what should be chosen as the primary analysis method? We see no 
single “right answer” to meet all circumstances, but the following insights should help in 
making the choice: 
 
1) PS matching appears to be a reliable method in that it provides excellent covariate balance 
in most circumstances. It has the advantage of being simple to analyse, present and interpret. 
Its main disadvantage is that some individuals end up not matched and hence excluded from 
the analysis, resulting in a loss of both precision and generalizability. In our examples, up to 
60% of patients were excluded by matching, although it should be noted that some of these 
patients could have been successfully matched by using more sophisticated matching 
algorithms. Finally, whatever the choice of matching algorithm, it is important to pre-define 
the precise algorithm to be used.  
 
2) PS stratification tends to work well when covariate imbalance is not very marked. It has 
the merit of keeping all individuals in the analysis and also provides the opportunity to 
explore potential interactions between treatment and the PS on outcome risk. Stratification 
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tends to perform less well in datasets with few outcomes, particularly when the number of 
strata is large. When choosing the number of strata, one needs to trade-off the need for 
accurate control of confounding with the requirement of having a sufficient number of events 
in each stratum. Previous research shows that 5 strata may reduce confounding bias by up to 
90%, so a modest number of strata should suffice in studies with few outcomes and/or only 
moderate confounding bias.[25] However, in studies with many outcome events using up to 10 
strata will further reduce confounding bias, which may be important if covariate imbalance is 
marked.[26, 27]   Beyond these recommendations, further research is needed to determine the 
best strategy to define the number and size distribution of strata. Are equal size strata 
preferred, or is it better to have larger numbers in the middle of the PS distribution, therefore 
enabling a more detailed exploration of the tails? 
 
3) Inverse probability weighting (IPW) offers a conceptually simple method that is easy to 
implement in practice and retains all study participants. Some have advocated it as a 
preferred method[28, 29] However, when there is marked covariate imbalance, PS scores close 
to the extreme probabilities of 0 and 1occur, with some individuals ending up with very large 
weights. This seems intuitively inappropriate since these influential data points occur in 
individuals who represent a small proportion in their chosen treatment group. In our two 
examples with such extreme weights, THIN and PROMETHEUS, use of IPW produced less 
precise estimates than other methods and notable covariate imbalance.  
 
Trimming has been recommended as an appropriate way of limiting the influence of heavily-
weighted individuals. The difficulty here is to define in advance what level of trimming is 
desirable: should we exclude just 1% or up to 5% of extreme weights? In our examples with 
major covariate imbalance, trimming increased the precision of our estimates but did not alter 
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the estimated associations. Truncating large weights resulted in more precise estimates and 
had large effects on the estimated associations. In both our examples, the estimated 
associations moved closer to the crude HR following truncation, perhaps suggesting that this 
method may lead to inadequate adjustment for covariate imbalance. Given the difficulty of 
limiting the influence of heavily weighted individuals, IPW may be best confined to datasets 
for which extremes of the PS distribution do not occur, such as in CHARM and ADAPT-
DES, although this will generally not be known in advance of examining the data 
distribution.  
 
Using a “doubly robust” IPW approach, where covariates are also included in the outcome 
regression model, appeared to produce results similar to traditional coverage adjustment, but 
with notably wider CIs. They also add a level of complexity to the analysis, and the inclusion 
of covariates in the outcome regression model removes a key advantage of the propensity 
score methods. They may therefore be unattractive as a primary method of analysis, and be 
best reserved for sensitivity explorations. 
 
 
4) Covariate adjustment is the traditional method for correcting for covariate imbalance, 
selection bias and potential confounding, and existed long before PS methods were 
developed. Recently, some have argued that PS methods may be more robust or offer more 
complete adjustment for confounders.[28]  However, whilst there are theoretical grounds on 
which to favor propensity score adjustment, we see little practical evidence to justify such 
negative claims[30]and in our examples, covariate adjustment provided reliable and 
statistically efficient estimates. One issue for datasets with few event outcomes is that the 
number of covariates considered for inclusion in the model may be limited, whereas many 
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more covariates may be included in a PS model without raising concerns of over-fitting or 
lack of model convergence. However, in ADAPT-DES including 39 covariates with only 56 
events still produced reliable results. This example demonstrates that having fewer than 10 
events per covariate does not necessary preclude using covariate adjustment[7], although it 
does not allay concerns of over-fitting in all similar scenarios. A further advantage of 
covariate adjustment is that it provides a predictive model (including treatment) for the risk 
(hazard) of the event outcome, which gives insight as to which covariates have the strongest 
influence on risk. Perhaps it is time that old-fashioned covariate adjustment deserves a revival 
in its use. Finally, adding the propensity score as an additional covariate produced results 
very similar to covariate adjustment, with similar estimates and standard errors across all 
examples. 
 
Our study has limitations. Firstly, with just four datasets explored in depth, caution is needed 
in drawing any generalizable conclusions. This is particularly the case for small studies which 
are not examined here, although it should be noted that ADAPT-DES is small in terms of the 
number of outcome events included. Despite these limitations, we feel that the diversity of 
our examples facilitate a practical debate based on real experiences, which is better than 
relying on purely theoretical arguments.  Secondly, our study assumes throughout that the 
effect of treatment on outcome does not differ by the likelihood that a patient is treated. 
When treatment effects do differ, as can be detected by comparing estimated HRs across 
strata of the PS, some PS methods will produce results that are systematically different from 
covariate adjustment even when both methods provide adequate adjustment for 
confounders.[31] This is because certain PS methods estimate the treatment effects relating to 
certain sections of the study population, such as only the treated or only the control patients. 
In these scenarios, investigators need to select an appropriate method to estimate the 
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treatment effect in the set of patients in whom they most want to understand the impact of 
treatment: usually this is either the treated patients, the control patients, or the entire study 
population.[11] In addition a further technical detail is that IPW and PS matching (using an 
unpaired analyses) both estimate a marginal treatment effect, whereas multivariate regression, 
stratification and doubly robust methods all estimate a conditional HR. 
 
 
In conclusion, in the present detailed examination of alternative PS methods and covariate 
adjustment in several topical cardiovascular studies, covariate adjustment and matching 
performed well in all of our examples, although matching tended to give less precise 
estimates in some cases.  PS methods are not necessarily superior to traditional covariate 
adjustment, and care should be taken to select the most suitable method. We hope these 
insights will guide others to make wise choices in their use of PS methods, and to rekindle 
interest in old-fashioned covariate adjustment, which may be viewed as a suitable primary 
analysis method in many cases. 
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Figure Legends 
Central Illustration. An overview of the pros and cons of covariate adjustment and various 
propensity score methods. 
 
Figure 1. Overview of the propensity score distribution for the “control” (blue) and 
“treatment” (red) exposures for: a) CHARM; b) ADAPT-DES; c) THIN; and d) 
PROMETHEUS. 
 
Figure 2. Comparison of hazard ratios from different PS methods and covariate 
adjustment for a) CHARM; b) ADAPT-DES; c) THIN; d) PROMETHEUS. 
In the plot, covariate adjustment is used as basis for the comparison (dashed line). Colors are 
used if results for the other methods differ by more than 5%. 
 
Figure 3. Distribution of the weights for IPW in: a) THIN; b) PROMETHEUS.  
To facilitate display, the vertical axis is on a logarithmic scale. There are no patients with 
extreme weights in the clopidogrel group, hence all patients treated with appear in the bar 
with the smallest inverse probability weight.  
 
Figure 4.Comparison of the extent of covariate imbalance in PROMETHEUS using: a) 
crude comparisons; b) propensity matching  c) propensity stratification; d) IPW. Graphs 
show the absolute standardized difference between treatment and control; values <0.1 are 
conventionally considered acceptable.  
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Central illustration 
 
 provides a prognostic model for outcome of interest
 may not be suitable with many covariates in smaller studies
Matching
 simple presentation of results
 loss of information for unmatched patients
Stratification
 provides effect estimates for every stratum
 may not fully account for strong confounding
Inverse probability weighting 
 creates a pseudo population with perfect covariate balance
 can be unstable when extreme weights occur
• Covariate adjustment works well in many cases
• Sensitivity analyses can help show consistency of 
findings across alternative propensity score method
• Unmeasured confounding can still cause bias with 
any of these methods
Propensity score methods
Covariate adjustment
Conclusions
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